Elan Pharma International Limited

Sterling Winthrop Inc.

Nanosystems L.l.c.

Fournier Laboratories Ireland Limited

Eastman-kodak Company

Alkermes Pharma Ireland Limited

Flak Pharma International, Ltd.

Sterling Wintrhop Inc.

Bgp Products Ireland Limited

Stephen B Ruddy

Eugene Rex Cooper

Mary E Roberts

Gary G Liversidge

Rajeev A Jain

Gregory L McIntire

W Mark Eickhoff

Rakesh A Patel

Niels Peter Ryde

Tuula Ryde

Evan E Gustow

Michael John Wilkins

Sui-Ming Wong

David A Engers

Shuqian Xu

Joost Strasters

John L Schaefer

John R Chippari

John A Bullock

Edward R Bacon

Pramod P Sarpotdar

Kathleen J Illig

Carl R Illig

John L Toner

H William Bosch

Brent D Douty

Kevin D Ostrander

Kimberly G Estep

Gurvinder Singh Rekhi

David Manser

Douglas C Hovey

Laura Kline

Maurice Joseph Anthony Clancy

Janet Elizabeth Codd

Kenneth Iain Cumming

Greta G Cary

Thomas J Caulifield

Elaine Merisko-Liversidge

Vaghefi Farid

Rajeev Jain

Rajeev c/o Elan Drug Delivery Jain

An abuse-resistant controlled release pharmaceutical composition comprising a pharmaceutically effective amount of discrete particles of an active capable of abuse, wherein surfaces of said particles are wetted with a water insoluble coating material, and preferably wherein said composition comprises a matrix, in which said particles are distributed, and which renders the abuse-capable compound within the matrix difficult to separate from the matrix; and a method for the preparation of a controlled release pharmaceutical composition having a reduced potential for abuse, comprising applying a pressure force to a mixture comprising a water insoluble material, and particles of a pharmaceutically active compound capable of inducing in a subject a reaction that is physiologically or psychologically detrimental if administered in an immediate release dosage form, thereby resulting in surface coated particles, and incorporating said surface coated particles into a pharmaceutical composition.

Abuse-resistant pharmaceutical compositions

Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.

In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions

Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors

The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.

Nanoparticulate fibrate formulations

Methods of treatment using nanoparticulate fenofibrate compositions

[object Object]

Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one active ingredient having a microparticulate particle size.

Compositions having a combination of immediate release and controlled release characteristics

Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.

Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect.

Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract

Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.

Rapidly disintegrating solid oral dosage form

The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.

Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors

Growing community of inventors

Schwenksville, PA, United States of America

Stephen B Ruddy